Madrigal Pharmaceuticals (MDGL) slides as insider sale headlines hit and investors take profits

Madrigal Pharmaceuticals (MDGL) is down 6.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The drop appears tied to fresh insider-selling disclosures and related headlines, which can pressure sentiment in a high-expectations biotech even when fundamentals are unchanged. This move also looks consistent with a bout of profit-taking after a strong multi-month run, with investors sensitive to valuation and near-term execution risk around the Rezdiffra launch.

Details:

A Form 4 disclosure showed Chief Medical Officer David Soergel sold shares on June 1, 2026, an event that often triggers short-term selling pressure despite being relatively small versus total insider holdings.

The company’s quarterly filing discussed the use of a Rule 10b5-1 trading plan for Soergel, which can indicate the transaction was pre-scheduled rather than a discretionary view on the business.

Recent company updates have emphasized continued commercial ramp activities for Rezdiffra; without a same-day clinical or regulatory headline, the market may have focused on trading/positioning rather than new fundamentals.

This could also be amplified by momentum-driven investors reducing exposure after a strong period for liver-disease-focused biotech names.

Sources:

SEC (EDGAR), Madrigal Pharmaceuticals (SEC filings/IR), StockTitan, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MDGL Insider Trading Activity

$MDGL insiders have traded $MDGL stock on the open market 131 times in the past 6 months. Of those trades, 0 have been purchases and 131 have been sales.

Here’s a breakdown of recent trading of $MDGL stock by insiders over the last 6 months:

PAUL A FRIEDMAN has made 0 purchases and 38 sales selling 49,600 shares for an estimated $26,657,462.
REBECCA TAUB has made 0 purchases and 42 sales selling 40,676 shares for an estimated $21,675,986.
MARDI DIER (EVP and CFO) has made 0 purchases and 28 sales selling 7,338 shares for an estimated $3,772,798.
RICHARD S LEVY has made 0 purchases and 12 sales selling 5,682 shares for an estimated $2,928,716.
WILLIAM JOHN SIBOLD (President and CEO) has made 0 purchases and 3 sales selling 5,640 shares for an estimated $2,875,678.
DAVID SOERGEL (Chief Medical Officer) has made 0 purchases and 2 sales selling 1,886 shares for an estimated $951,980.
CAROLE HUNTSMAN (Chief Commercial Officer) has made 0 purchases and 3 sales selling 1,329 shares for an estimated $630,321.
SHANNON T KELLEY (General Counsel) has made 0 purchases and 3 sales selling 1,052 shares for an estimated $499,671.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive MDGL Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$MDGL Hedge Fund Activity

We have seen 195 institutional investors add shares of $MDGL stock to their portfolio, and 220 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CITADEL ADVISORS LLC added 417,709 shares (+1156.0%) to their portfolio in Q1 2026, for an estimated $218,658,130
PAULSON & CO. INC. removed 315,334 shares (-18.5%) from their portfolio in Q1 2026, for an estimated $165,067,888
JANUS HENDERSON GROUP PLC removed 257,847 shares (-14.0%) from their portfolio in Q4 2025, for an estimated $150,154,621
WELLINGTON MANAGEMENT GROUP LLP added 233,556 shares (+50.6%) to their portfolio in Q1 2026, for an estimated $122,259,559
BANK OF AMERICA CORP /DE/ removed 226,498 shares (-54.4%) from their portfolio in Q1 2026, for an estimated $118,564,908
ALKEON CAPITAL MANAGEMENT LLC removed 160,000 shares (-66.7%) from their portfolio in Q1 2026, for an estimated $83,755,200
TORONTO DOMINION BANK added 130,460 shares (+inf%) to their portfolio in Q1 2026, for an estimated $68,291,896

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MDGL Analyst Ratings

Wall Street analysts have issued reports on $MDGL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Citizens issued a "Market Outperform" rating on 01/20/2026

To track analyst ratings and price targets for $MDGL, check out Quiver Quantitative's $MDGL forecast page.

$MDGL Price Targets

Multiple analysts have issued price targets for $MDGL recently. We have seen 9 analysts offer price targets for $MDGL in the last 6 months, with a median target of $670.0.

Here are some recent targets:

Srikripa Devarakonda from Truist Securities set a target price of $709.0 on 05/13/2026
Liisa Bayko from Evercore ISI Group set a target price of $649.0 on 05/07/2026
Edward Nash from Canaccord Genuity set a target price of $578.0 on 05/07/2026
Andrew S. Fein from HC Wainwright & Co. set a target price of $620.0 on 05/06/2026
Alexandria Hammond from B of A Securities set a target price of $529.0 on 02/20/2026
Eliana Merle from Barclays set a target price of $964.0 on 01/28/2026
Jonathan Wolleben from Citizens set a target price of $745.0 on 01/20/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.